文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

作者信息

Santoro Armando, Pilar Garrido, Tan Daniel S W, Zugazagoitia Jon, Shepherd Frances A, Bearz Alessandra, Barlesi Fabrice, Kim Tae Min, Overbeck Tobias R, Felip Enriqueta, Cai Can, Eddy Simantini, McCulloch Tracey, Schaefer Eric S

机构信息

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy.

出版信息

BMC Cancer. 2024 Nov 21;24(1):1436. doi: 10.1186/s12885-024-13210-9.

DOI:10.1186/s12885-024-13210-9
PMID:39574037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11580551/
Abstract
摘要

相似文献

[1]
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

BMC Cancer. 2024-11-21

[2]
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

BMC Cancer. 2024-10-24

[3]
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.

Future Oncol. 2022-5

[4]
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.

BMJ Open. 2024-8-29

[5]
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.

Front Oncol. 2022-8-10

[6]
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.

J Thorac Oncol. 2024-2

[7]
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.

J Clin Oncol. 2024-1-10

[8]
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.

Clin Cancer Res. 2021-12-1

[9]
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.

Clin Cancer Res. 2022-6-1

[10]
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.

Ann Oncol. 2022-5

本文引用的文献

[1]
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

BMC Cancer. 2024-10-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索